Anushua Sinha

Summary

Affiliation: New Jersey
Country: USA

Publications

  1. ncbi Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis
    Anushua Sinha
    Department of Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey New Jersey Medical School, Newark NJ 07101, USA
    Lancet 369:389-96. 2007
  2. ncbi Economic burden of acute lower respiratory tract infection in South African children
    Anushua Sinha
    Department of Preventive Medicine and Community Health, New Jersey Medical School, Newark, USA
    Paediatr Int Child Health 32:65-73. 2012
  3. ncbi Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis
    Anushua Sinha
    University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey 07090, United States of America
    Rev Panam Salud Publica 24:304-13. 2008
  4. ncbi Costs and consequences associated with newer medications for glycemic control in type 2 diabetes
    Anushua Sinha
    Center for Healthcare KnowledgeManagement, Veterans Health Administration New Jersey, East Orange, New Jersey, USA
    Diabetes Care 33:695-700. 2010
  5. ncbi Disappearance of vaccine-type invasive pneumococcal disease and emergence of serotype 19A in a minority population with a high prevalence of human immunodeficiency virus and low childhood immunization rates
    Azadeh Tasslimi
    Department of Preventive Medicine and Community Health, New Jersey Medical School UMDNJ, MSB F594, Newark, NJ 07103, USA
    Clin Vaccine Immunol 16:1256-9. 2009
  6. ncbi Invasive pneumococcal disease in an underimmunized, high HIV prevalence population
    Azadeh Tasslimi
    UMDNJ School of Public Health, 65 Bergen Street, Newark, NJ 07107, USA
    J Infect 56:99-102. 2008
  7. ncbi Estimating utilities for chronic kidney disease, using SF-36 and SF-12-based measures: challenges in a population of veterans with diabetes
    Mangala Rajan
    Center for Healthcare Knowledge Management, Veterans Health Administration New Jersey, East Orange, NJ, USA
    Qual Life Res 22:53-64. 2013

Research Grants

  1. CONSEQUENCES OF GROUP B STREPTOCOCCAL PROPHYLAXIS
    Anushua Sinha; Fiscal Year: 2004

Collaborators

Detail Information

Publications7

  1. ncbi Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis
    Anushua Sinha
    Department of Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey New Jersey Medical School, Newark NJ 07101, USA
    Lancet 369:389-96. 2007
    ..Our aim was to incorporate these data into an economic analysis of pneumococcal vaccination of infants in countries eligible for financial support from the Global Alliance for Vaccines & Immunization (GAVI)...
  2. ncbi Economic burden of acute lower respiratory tract infection in South African children
    Anushua Sinha
    Department of Preventive Medicine and Community Health, New Jersey Medical School, Newark, USA
    Paediatr Int Child Health 32:65-73. 2012
    ..Acute lower respiratory tract infections (ALRTI) are a leading cause of childhood mortality, but there are few data on disease costs in developing countries...
  3. ncbi Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis
    Anushua Sinha
    University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey 07090, United States of America
    Rev Panam Salud Publica 24:304-13. 2008
    ..Our aim was to incorporate vaccine, demographic, epidemiologic, and cost data into an economic analysis of pneumococcal vaccination of infants in Latin America and the Caribbean...
  4. ncbi Costs and consequences associated with newer medications for glycemic control in type 2 diabetes
    Anushua Sinha
    Center for Healthcare KnowledgeManagement, Veterans Health Administration New Jersey, East Orange, New Jersey, USA
    Diabetes Care 33:695-700. 2010
    ..We undertook a health economic analysis to better understand the value of adding two newer medications (exenatide and sitagliptin) as second-line therapy to glycemic control strategies for patients with new-onset diabetes...
  5. ncbi Disappearance of vaccine-type invasive pneumococcal disease and emergence of serotype 19A in a minority population with a high prevalence of human immunodeficiency virus and low childhood immunization rates
    Azadeh Tasslimi
    Department of Preventive Medicine and Community Health, New Jersey Medical School UMDNJ, MSB F594, Newark, NJ 07103, USA
    Clin Vaccine Immunol 16:1256-9. 2009
    ..We observed near-elimination of vaccine-type IPD. Substantial disease remains due to non-vaccine-type pneumococci, highlighting the need to increase pneumococcal immunization among HIV-infected adults...
  6. ncbi Invasive pneumococcal disease in an underimmunized, high HIV prevalence population
    Azadeh Tasslimi
    UMDNJ School of Public Health, 65 Bergen Street, Newark, NJ 07107, USA
    J Infect 56:99-102. 2008
    ..To describe the epidemiology of invasive pneumococcal disease (IPD) in a predominantly minority population with low childhood immunization rates and high HIV prevalence, during the early childhood pneumococcal vaccine (PCV7) era...
  7. ncbi Estimating utilities for chronic kidney disease, using SF-36 and SF-12-based measures: challenges in a population of veterans with diabetes
    Mangala Rajan
    Center for Healthcare Knowledge Management, Veterans Health Administration New Jersey, East Orange, NJ, USA
    Qual Life Res 22:53-64. 2013
    ..We used within-method and across-method comparisons and estimated disutilities associated with increasing chronic kidney disease (CKD) severity...

Research Grants1

  1. CONSEQUENCES OF GROUP B STREPTOCOCCAL PROPHYLAXIS
    Anushua Sinha; Fiscal Year: 2004
    ..This application for a K23 award combines coursework, a research plan, and personal mentoring to train Anushua Sinha M.D., M.P.H. for independence as a clinical investigator. Dr...